Aerogel sponges of silk fibroin, hyaluronic acid and heparin for soft tissue engineering: Composition-properties relationship

Thumbnail Image

Files

2020_CarbPol_Najberg_Aerogel.pdf (821.18 KB)
Identifiers
URI: https://hdl.handle.net/10347/45182
ISSN: 1879-1344
DOI: 10.1016/j.carbpol.2020.116107

Publication date

2020-03-03

Authors

Advisors

Tutors

Editors

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier
Metrics
Google Scholar
lacobus
Export

Research Projects

Organizational Units

Journal Issue

Abstract

This work aims to design biocompatible aerogel sponges that can host and control the release of stromal cell-derived factor-1α (SDF-1α or CXCL12), a key protein for applications ranging from regenerative medicine to cancer therapy (notably for neural tissues). Miscibility of silk fibroin (SF) and hyaluronic acid (HA) was investigated by means of fluorescence and scanning electron microscopy to identify processing conditions. Series of freeze-dried sponges were prepared by associating and cross-linking within the same 3D structure, HA, SF, poly-l-lysine (PLL) and heparin (hep). Aerogel sponges presented high swelling degree and porosity (∼90 %), adequate mean pore diameter (ca. 60 μm) and connectivity for welcoming cells, and a soft texture close to that of the brain (6–13 kPa Young’s Modulus). Addition of SF yielded sponges with slower biodegradation. SF-HA and SF-HA-hep sponges retained 75 % and 93 % of the SDF-1α respectively after 7 days and were found to be cytocompatible in vitro

Description

Keywords

Brain biomimicry| SDF-1α controlled release| Porous scaffold| Aerogel sponges| Silk fibroin

Bibliographic citation

Relation

Has part

Has version

Is based on

Is part of

Is referenced by

Is version of

Requires

Sponsors

This work was supported by the “Institut National de la Santé et de la Recherche Médicale” (INSERM), University of Angers (Angers, France), MINECO (SAF2017-83118-R), Agencia Estatal de Investigacion (AEI, Spain), Fondo Europeo de Desarollo Regional (FEDER), and COST AERoGELS CA18125 European Commission. The work was also supported by the French National Research Agency (ANR) and the National Institute of Health Carlos III (ISCIII), under the frame of EuroNanoMed III (GLIOSILK project). The authors thank also the "Région Pays de la Loire" for fundings in the framework of the project "International strategy NANOFAR+". MN was a Ph.D. student involved in the Erasmus Mundus Joint Doctorate program for Nanomedicine and Pharmaceutical Innovation (EMJD NanoFar). She received a fellowship from “La Région Pays-de-la-Loire”. EG and MN were also members of the LabEx IRON “Innovative Radiopharmaceuticals in Oncology and Neurology” as part of the French government “Investissements d’Avenir” program, and of the Cancéropôle Grand-Ouest (tumor targeting and radiotherapy network). RMP and MHM were PhD fellows from the “Ministère de lʼEnseignement supérieur, de la Recherche et de lʼInnovation” (MESRI). The authors acknowledge the help given by R. Varela Calviño (USC) for SDS-PAGE experiments

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

Collections

Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica
Instituto de Materiais (iMATUS)